James J Falk

US Patent:

8311622, Nov 13, 2012

Filed:

Nov 30, 2006

Appl. No.:

11/565305

Inventors:

Steven M. Snyder - Boulder CO, US
James D. Falk - Duluth MN, US

Assignee:

Neba Health LLC - Augusta GA

International Classification:

A61B 5/0467

US Classification:

600544, 600300

Abstract:

This invention is directed to systems and methods for analyzing depression, and more particularly relates to systems and methods for analyzing and assessing depression and mood disorders in an individual using electroencephalographic measurements. Embodiments of the invention are not limited to depression, but can also include other mood disorders such as bipolar disorder and other disorders with at least one genetic-related component.

US Patent:

8509885, Aug 13, 2013

Filed:

Sep 26, 2012

Appl. No.:

13/627382

Inventors:

James D. Falk - Duluth MN, US

Assignee:

Neba Health LLC - Augusta GA

International Classification:

A61B 5/0476

US Classification:

600544

Abstract:

This invention is directed to systems and methods for analyzing depression, and more particularly relates to systems and methods for analyzing and assessing depression and mood disorders in an individual using electroencephalographic measurements. Embodiments of the invention are not limited to depression, but can also include other mood disorders such as bipolar disorder and other disorders with at least one genetic-related component.

US Patent:

20070299360, Dec 27, 2007

Filed:

Jun 21, 2007

Appl. No.:

11/766615

Inventors:

Steven M. Snyder - Boulder CO, US
James D. Falk - Duluth MN, US

Assignee:

LEXICOR MEDICAL TECHNOLOGY, LLC - Augusta GA

International Classification:

A61B 5/0476

US Classification:

600544

Abstract:

Embodiments of the invention can provide systems and methods for analyzing and assessing dementia and dementia-type disorders by integrating the use of electroencephalography (EEG), neuropsychological or cognitive testing data, and cardiovascular risk factor data. Embodiments of the invention can provide systems and methods for early detection of dementia, including Alzheimer's disease (AD), vascular dementia (VAD), mixed dementia (AD and VAD), MCI, and other dementia-type disorders. Embodiments of the invention can provide some or all of the following improvements over conventional systems and methods, including: (1) Increased sensitivity, specificity, and overall accuracy; (2) Detection of AD, VAD and mixed dementia; and (3) Accurate detection of mild dementia and some cases of mild cognitive impairment in addition to the detection of moderate to severe dementia.